Authors
Latest:
Ireland’s Role in the European Union’s Evolving Pharmaceutical SectorRory Mullen outlines Ireland’s importance to multinational pharma in the changing EU landscape.
Latest:
The Fruits of Comparative EffectivenessNew CER tools grant payers the evidence they need to control drug costs
Latest:
Plant ManagementWe ask three managers building Greenfield plants to rationalize and defend their decisions
Latest:
FDA Feels Pinch of House Funding CutsThe House Appropriations Committee released the fiscal year 2013 Agriculture Appropriations bill, which, sets proposed spending levels for FDA as well as for other programs.
Latest:
AI-based Social Listening as Aid to PharmacovigilanceHow artificial intelligence can help pharma filter out the online noise when monitoring for safety signals on the web.
Latest:
Country Report: The Czech RepublicAlthough still tightly regulated, healthcare industry stakeholders-buoyed by regulatory reforms aimed at increasing patient access to innovative new therapies-are cautiously optimistic that the Czech Republic will further close the gap with Western Europe.
Latest:
The Fruits of Comparative EffectivenessNew CER tools grant payers the evidence they need to control drug costs
Latest:
A Forecasting Rx for Pharmacy Benefit ManagersBuilding an effective drug forecasting model today requires a revamped approach.
Latest:
The '3S' Framework for Post-Deal Growthpartnerships, big pharma, data exchange, Business Development, M&A, Business Strategy, information exchange, dealmaking, Rebecca Ashkenazy, Alex Chang, Cyndi Green, Ted Miller, Christine de los Reyes, targeted medicine, R&D productivity
Latest:
The '3S' Framework for Post-Deal Growthpartnerships, big pharma, data exchange, Business Development, M&A, Business Strategy, information exchange, dealmaking, Rebecca Ashkenazy, Alex Chang, Cyndi Green, Ted Miller, Christine de los Reyes, targeted medicine, R&D productivity
Latest:
The '3S' Framework for Post-Deal Growthpartnerships, big pharma, data exchange, Business Development, M&A, Business Strategy, information exchange, dealmaking, Rebecca Ashkenazy, Alex Chang, Cyndi Green, Ted Miller, Christine de los Reyes, targeted medicine, R&D productivity
Latest:
The '3S' Framework for Post-Deal Growthpartnerships, big pharma, data exchange, Business Development, M&A, Business Strategy, information exchange, dealmaking, Rebecca Ashkenazy, Alex Chang, Cyndi Green, Ted Miller, Christine de los Reyes, targeted medicine, R&D productivity
Latest:
The '3S' Framework for Post-Deal Growthpartnerships, big pharma, data exchange, Business Development, M&A, Business Strategy, information exchange, dealmaking, Rebecca Ashkenazy, Alex Chang, Cyndi Green, Ted Miller, Christine de los Reyes, targeted medicine, R&D productivity
Latest:
The Changing Landscape of Digital TrialsRichard Young, Vice President of Strategy, Vault CDMS and Tim Davis, Vice President of Strategy, MyVeeva for Patients, discuss the future of digital trials and their impact in the industry.
Latest:
The Pharma Leadership Challenge: Thawing the “Frozen” Middle ManagersThe challenge for senior leadership is to enable the layers of middle management to work to their full potential. Mike Straw argues that ‘failing fast’ should become the new mantra if pharma is going to drive greater innovation and creativity.
Latest:
Market Access in UkraineOn September 16, 2014, the Ukrainian and European parliaments ratified the EU–Ukraine Association Agreement (AA), providing for harmonization of many spheres of Ukrainian legislation with EU policy.
Latest:
Market Access in UkraineOn September 16, 2014, the Ukrainian and European parliaments ratified the EU–Ukraine Association Agreement (AA), providing for harmonization of many spheres of Ukrainian legislation with EU policy.
Latest:
Customer Engagement Isnt Just About Physicians Its About Sales Reps TooManaging the pharma sales force has always been challenging. Reps are spread out geographically, often far from corporate offices, preventing them from taking part in the on-site activities and face-to-face interactions that typically foster a connection to the company.
Latest:
What AR (Augmented Reality) & Apple Vision Pro Could Mean to Health & Life Sciences Sector Navigating the New RealityEVERSANA's chief innovation discusses his experience with Apple's new device and how he thinks it might impact the life sciences industry.
Latest:
Value-Based Healthcare in the UKJill E. Sackman and Michael Kuchenreuther look at some of the pricing and reimbursement challenges in the UK and offer strategies manufacturers should consider for sustainable success.
Latest:
Europe Sees Pressure to Reduce Environmental Impact of PharmaceuticalsPressure is mounting on European legislators to introduce tighter regulations at both the European Union (EU) and national levels on the potentially harmful impact of pharmaceuticals on the environment.
Latest:
New Social Media Guidelines: What FDA Says, and What It MeansEarlier this year, FDA promised three sets of guidelines to clarify using social media for pharma marketing. Last week it delivered two of them
Latest:
EU Strengthens Transatlantic LinksThe European Union's extensive links with the US FDA and Health Canada have reached a further level of maturity, writes Peter O' Donnell.
Latest:
Lilly Launches Online Training for Patient AdvocatesAn interactive training program designed “to help patient advocates better influence decisions related to access to new medicines” was launched today by Eli Lilly.
Latest:
Behind the Buzzwords Patient Personas are PowerfulBig, bold, blustering buzzwords are as much a part of the digital marketing landscape as the innovative, enabling technologies that spawn them. New techniques, even new spins on old techniques, demand new terminology.
Latest:
Omnicom & Publicis 5 Questions to Frame the DealSince the Omnicom-Publicis merger was announced in late July, it appears the only sources that have not commented on the joining of the superpowers are the President, the Pope, and WikiLeaks.
Latest:
Crisis Preparedness in an Always-On Digital WorldThe first 120 minutes of a crisis can determine the public’s perception of an organization. And in today’s digital world, companies are more at risk than ever to viral attacks from unexpected sources.
